LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 24.0
(-1.44%)
TWD 24.0
(-1.44%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 60.81 Million TWD | 476.98% |
| 2022 | 10.54 Million TWD | 21.41% |
| 2021 | 8.68 Million TWD | -67.9% |
| 2020 | 27.04 Million TWD | -81.7% |
| 2019 | 147.77 Million TWD | 1758.6% |
| 2018 | 7.95 Million TWD | -79.75% |
| 2017 | 39.27 Million TWD | -78.94% |
| 2016 | 186.52 Million TWD | 27.56% |
| 2015 | 146.22 Million TWD | -29.07% |
| 2014 | 206.13 Million TWD | -64.97% |
| 2013 | 588.38 Million TWD | 28.91% |
| 2012 | 456.41 Million TWD | 107.11% |
| 2011 | 220.36 Million TWD | 390.69% |
| 2010 | 44.91 Million TWD | 7.02% |
| 2009 | 41.96 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 46.75 Million TWD | -21.45% |
| 2024 Q3 | 31.74 Million TWD | -32.09% |
| 2024 Q1 | 59.52 Million TWD | -2.14% |
| 2023 Q2 | 26.05 Million TWD | 185.17% |
| 2023 FY | 60.81 Million TWD | 476.98% |
| 2023 Q1 | 9.13 Million TWD | -13.32% |
| 2023 Q4 | 60.81 Million TWD | 134.86% |
| 2023 Q3 | 25.89 Million TWD | -0.61% |
| 2022 FY | 10.54 Million TWD | 21.41% |
| 2022 Q4 | 10.54 Million TWD | -11.08% |
| 2022 Q3 | 11.85 Million TWD | -9.07% |
| 2022 Q2 | 13.03 Million TWD | 30.47% |
| 2022 Q1 | 9.99 Million TWD | 15.1% |
| 2021 Q1 | 16.96 Million TWD | -37.25% |
| 2021 Q4 | 8.68 Million TWD | -0.4% |
| 2021 Q3 | 8.71 Million TWD | 2.28% |
| 2021 FY | 8.68 Million TWD | -67.9% |
| 2021 Q2 | 8.52 Million TWD | -49.77% |
| 2020 FY | 27.04 Million TWD | -81.7% |
| 2020 Q4 | 27.04 Million TWD | -44.1% |
| 2020 Q3 | 48.37 Million TWD | -37.88% |
| 2020 Q1 | 148.52 Million TWD | 0.5% |
| 2020 Q2 | 77.86 Million TWD | -47.57% |
| 2019 FY | 147.77 Million TWD | 1758.6% |
| 2019 Q4 | 147.77 Million TWD | 120.17% |
| 2019 Q2 | 11.62 Million TWD | 24.23% |
| 2019 Q1 | 9.36 Million TWD | 17.72% |
| 2019 Q3 | 67.12 Million TWD | 477.23% |
| 2018 Q3 | 31.67 Million TWD | 0.41% |
| 2018 Q1 | 38.95 Million TWD | -0.81% |
| 2018 FY | 7.95 Million TWD | -79.75% |
| 2018 Q4 | 7.95 Million TWD | -74.9% |
| 2018 Q2 | 31.54 Million TWD | -19.03% |
| 2017 Q3 | 116.63 Million TWD | 25.41% |
| 2017 Q2 | 93 Million TWD | -28.61% |
| 2017 Q1 | 130.27 Million TWD | -30.16% |
| 2017 FY | 39.27 Million TWD | -78.94% |
| 2017 Q4 | 39.27 Million TWD | -66.33% |
| 2016 Q1 | 134.23 Million TWD | -8.2% |
| 2016 FY | 186.52 Million TWD | 27.56% |
| 2016 Q4 | 186.52 Million TWD | -25.18% |
| 2016 Q3 | 249.29 Million TWD | 43.97% |
| 2016 Q2 | 173.16 Million TWD | 29.0% |
| 2015 Q3 | 153.63 Million TWD | -0.94% |
| 2015 Q4 | 146.22 Million TWD | -4.83% |
| 2015 FY | 146.22 Million TWD | -29.07% |
| 2015 Q1 | 138.81 Million TWD | -32.66% |
| 2015 Q2 | 155.09 Million TWD | 11.73% |
| 2014 Q1 | 221.57 Million TWD | -62.34% |
| 2014 Q4 | 206.13 Million TWD | -37.95% |
| 2014 FY | 206.13 Million TWD | -64.97% |
| 2014 Q3 | 332.2 Million TWD | -9.36% |
| 2014 Q2 | 366.52 Million TWD | 65.42% |
| 2013 Q2 | 559.26 Million TWD | 15.92% |
| 2013 Q4 | 588.38 Million TWD | -17.24% |
| 2013 FY | 588.38 Million TWD | 28.91% |
| 2013 Q1 | 482.45 Million TWD | 5.71% |
| 2013 Q3 | 710.93 Million TWD | 27.12% |
| 2012 Q4 | 456.41 Million TWD | 118.46% |
| 2012 Q3 | 208.92 Million TWD | -41.02% |
| 2012 FY | 456.41 Million TWD | 107.11% |
| 2012 Q2 | 354.21 Million TWD | 5.15% |
| 2012 Q1 | 336.85 Million TWD | 52.86% |
| 2011 Q3 | 465.14 Million TWD | 366.73% |
| 2011 Q4 | 220.36 Million TWD | -52.62% |
| 2011 Q2 | 99.66 Million TWD | -31.1% |
| 2011 Q1 | 144.63 Million TWD | 222.06% |
| 2011 FY | 220.36 Million TWD | 390.69% |
| 2010 FY | 44.91 Million TWD | 7.02% |
| 2010 Q4 | 44.91 Million TWD | 0.0% |
| 2009 FY | 41.96 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Grape King Bio Ltd | 737.18 Million TWD | 91.75% |
| Standard Chem & Pharm CO., LTD. | 1.61 Billion TWD | 96.234% |
| Maywufa Company Ltd. | 257.91 Million TWD | 76.419% |
| ScinoPharm Taiwan, Ltd. | 1.51 Billion TWD | 95.976% |
| Lotus Pharmaceutical Co., Ltd. | 3.77 Billion TWD | 98.389% |
| YungShin Global Holding Corporation | 2.77 Billion TWD | 97.807% |
| PhytoHealth Corporation | 163.09 Million TWD | 62.708% |
| SCI Pharmtech, Inc. | 529.53 Million TWD | 88.515% |
| Formosa Laboratories, Inc. | 1.59 Billion TWD | 96.193% |
| PharmaEssentia Corporation | 1.45 Billion TWD | 95.83% |
| Bora Pharmaceuticals Co., LTD. | 2.15 Billion TWD | 97.179% |